Reversion and conversion of interferon-γ release assay results in HIV-1-infected individuals.

ABSTRACT

In this prospective study, human immunodeficiency virus type 1 (HIV-1)-infected subjects underwent QuantiFERON-TB Gold In-Tube interferon-γ release assay (IGRA) testing at baseline and after 24 months in a low tuberculosis incidence country. Concordant baseline and follow-up results were observed in 86% (n = 686 of 794) of subjects. IGRA conversions occurred in 9% (n = 63 of 718), whereas IGRA reversions were seen in 33% (n = 25 of 76) of individuals. Of the 10 active tuberculosis cases during follow-up, 5 had concordant positive IGRA results and 2 were IGRA converters. Although the clinical significance of IGRA conversions and reversions remains to be established, repeated IGRA testing seems to be of value in HIV-1-infected individuals.